{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:40:27Z","timestamp":1791646827450,"version":"4.3.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jaad.2017.07.027","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T19:45:34Z","timestamp":1505331934000},"page":"1038-1046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa"],"prefix":"10.1016","volume":"77","author":[{"given":"Iltefat H.","family":"Hamzavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Zivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Parks-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Ganguli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R.","family":"Arikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2 Pt 1","key":"10.1016\/j.jaad.2017.07.027_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1067\/mjd.2000.106374","article-title":"Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?","volume":"43","author":"Krueger","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1365-2133.2001.04137.x","article-title":"Morbidity in patients with hidradenitis suppurativa","volume":"144","author":"Von Der Werth","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.07.027_bib3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1067\/mjd.2003.540","article-title":"Connections between psoriasis and Crohn\u2019s disease","volume":"48","author":"Najarian","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.027_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00341181","article-title":"The\u00a0differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn\u2019s disease","volume":"8","author":"Church","year":"1993","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.027_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1529-8019.2010.01312.x","article-title":"Psoriasis: depression, anxiety, smoking, and drinking habits","volume":"23","author":"Hayes","year":"2010","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.027_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jdv.12567","article-title":"Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa","volume":"29","author":"Shavit","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2017.07.027_bib7","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/archderm.141.12.1527","article-title":"Impact of obesity and smoking on psoriasis presentation and management","volume":"141","author":"Herron","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.027_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/jid.2012.255","article-title":"Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota","volume":"133","author":"Vazquez","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.07.027_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archdermatol.2010.370","article-title":"Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006","volume":"147","author":"Love","year":"2011","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jaad.2013.11.014","article-title":"The prevalence of metabolic syndrome in patients with hidradenitis suppurativa","volume":"70","author":"Gold","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2017.07.027_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1177\/000313480807401209","article-title":"Hidradenitis suppurativa complicated by squamous cell carcinoma","volume":"74","author":"Constantinou","year":"2008","journal-title":"Am Surg"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2017.07.027_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2017.07.027_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1468-3083.2000.00087.x","article-title":"The natural history of hidradenitis suppurativa","volume":"14","author":"von der Werth","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.027_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jssdds.2012.06.003","article-title":"Hidradenitis suppurativa (Verneuil\u2019s disease)","volume":"17","author":"Dhaou","year":"2013","journal-title":"Journal of the Saudi Society of Dermatology and Dermatologic Surgery"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2017.07.027_bib16","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.amjmed.2009.08.022","article-title":"Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis","volume":"123","author":"Kimball","year":"2010","journal-title":"Am J Med"},{"issue":"14","key":"10.1016\/j.jaad.2017.07.027_bib18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.027_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","article-title":"Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys","volume":"47","author":"Helmick","year":"2014","journal-title":"Am J Prev Med"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.027_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3949\/ccjm.79a.11133","article-title":"Psoriasis: evolving treatment for a complex disease","volume":"79","author":"Villase\u00f1or-Park","year":"2012","journal-title":"Cleve Clin J Med"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.027_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5021\/ad.2016.28.2.147","article-title":"Management of hidradenitis suppurativa in patients with metabolic comorbidities","volume":"28","author":"Lim","year":"2016","journal-title":"Ann Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bjd.14024","article-title":"Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies","volume":"173","author":"Tzellos","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2017.07.027_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1203475415602842","article-title":"Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database","volume":"20","author":"Lai","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib26","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bjd.14170","article-title":"Cardiovascular disease risk factors in patients with hidradenitis suppurativa","volume":"173","author":"Simpson","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.027_bib27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","article-title":"Evaluating the economic burden of psoriasis in the United States","volume":"72","author":"Vanderpuye-Orgle","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.07.027_bib28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamadermatol.2014.691","article-title":"Health care utilization patterns and costs for patients with hidradenitis suppurativa","volume":"150","author":"Kirby","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1067\/mjd.2000.107501","article-title":"The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms","volume":"43","author":"Wahl","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.027_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","article-title":"Quality of life in patients with psoriasis: a systematic literature review","volume":"9","author":"de Korte","year":"2004","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","article-title":"Determinants of quality of life in patients with psoriasis: a study from the US population","volume":"51","author":"Gelfand","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaad.2006.08.061","article-title":"Quality of life impairment in hidradenitis suppurativa: a study of 61 cases","volume":"56","author":"Wolkenstein","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1067\/mjd.2002.122755","article-title":"Quantifying the harmful effect of psoriasis on health-related quality of life","volume":"47","author":"Weiss","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib34","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"5 suppl 1","key":"10.1016\/j.jaad.2017.07.027_bib35","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","article-title":"Hidradenitis suppurativa: epidemiology and scope of the problem","volume":"73","author":"Jemec","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2017.07.027_bib36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2017.07.027_bib37","unstructured":"Armstrong A, Pinsky B, Sundaram M, Shu L, Okun M BY. Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): results from the first 12 weeks of PIONEER I. Paper presented at: 44th Annual European Society for Dermatological Research Meeting. September 10-13, 2014; Copenhagen, Denmark."},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib38","doi-asserted-by":"crossref","first-page":"AB38","DOI":"10.1016\/j.jaad.2015.02.166","article-title":"Adalimumab improves health-related quality of life (HRQoL) in patients with moderate to severe hidradenitis suppurativa (HS): results from the first 12 weeks of PIONEER II","volume":"72","author":"Armstrong","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.027_bib39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09546630701646172","article-title":"Impact of adalimumab treatment on patient-reported outcomes: results from a phase III clinical trial in patients with moderate to severe plaque psoriasis","volume":"18","author":"Revicki","year":"2007","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.027_bib40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.027_bib41","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jaad.2010.10.020","article-title":"The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis","volume":"66","author":"Kimball","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.027_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7525-4-71","article-title":"The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study","volume":"4","author":"Shikiar","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.027_bib43","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib44","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of\u00a0patients with severe psoriasis: a double-blind placebo-controlled trial","volume":"152","author":"Feldman","year":"2005","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.027_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2133.2004.05697.x","article-title":"Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis","volume":"150","author":"Feldman","year":"2004","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000069942","article-title":"Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis","volume":"206","author":"Finlay","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2017.07.027_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/09546630500482886","article-title":"The negative impact of psoriasis on the workplace","volume":"17","author":"Pearce","year":"2006","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.027_bib48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib49","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: effective in the management of hidradenitis suppurativa","volume":"154","author":"Cusack","year":"2006","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.027_bib50","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2133.2007.08332.x","article-title":"Long-term efficacy of a single course of infliximab in hidradenitis suppurativa","volume":"158","author":"Mekkes","year":"2008","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib51","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","article-title":"Hidradenitis suppurativa markedly decreases quality of life and professional activity","volume":"62","author":"Matusiak","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"S11","key":"10.1016\/j.jaad.2017.07.027_bib52","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1002\/acr.20543","volume":"63","author":"Hawker","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.027_bib53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and\u00a0reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.027_bib54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2017.07.027_bib55","series-title":"SF-36\u00ae Health Survey","author":"Turner-Bowker","year":"2008"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.027_bib56","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.027_bib57","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/beheco\/ark016","article-title":"The unequal variance t-test is an underused alternative to Student\u2019s t-test and the Mann-Whitney U test","volume":"17","author":"Ruxton","year":"2006","journal-title":"Behav Ecol"},{"issue":"12","key":"10.1016\/j.jaad.2017.07.027_bib58","doi-asserted-by":"crossref","first-page":"e52935","DOI":"10.1371\/journal.pone.0052935","article-title":"Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011","volume":"7","author":"Armstrong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jaad.2017.07.027_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"10.1016\/j.jaad.2017.07.027_bib60","doi-asserted-by":"crossref","first-page":"990","DOI":"10.2340\/00015555-2176","article-title":"Hidradenitis suppurativa disproportionately affects African Americans: a single-center retrospective analysis","volume":"95","author":"Vlassova","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2017.07.027_bib61","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/jdv.12233","article-title":"The impact of psoriasis on work-related problems: a multicenter cross-sectional survey","volume":"28","author":"Ayala","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2017.07.027_bib62","first-page":"16","article-title":"Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances","volume":"7","author":"Alexis","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2017.07.027_bib63","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/jid.2014.220","article-title":"Ethnicity and hidradenitis suppurativa","volume":"134","author":"Reeder","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.07.027_bib64","unstructured":"European Medicines Agency. First medicine recommended for approval for hidradenitis suppurativa; treatment of this serious skin condition to be added to Humira's approved uses. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2015\/06\/WC500188809.pdf. Accessed April 25, 2016."},{"key":"10.1016\/j.jaad.2017.07.027_bib65","unstructured":"Health Canada. Regulatory decision summary: humira. Available at: https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?lang=en&linkID=RDS00025. Published January 21, 2016. Accessed April 25, 2016."},{"key":"10.1016\/j.jaad.2017.07.027_bib66","unstructured":"Healio Dermatology. FDA approves Humira for moderate to severe hidradenitis suppurativa. Available at: http:\/\/www.healio.com\/dermatology\/practice-management\/news\/online\/%7Bb5ae3a1a-7e99-4e02-b066-1c2cb91a6160%7D\/fda-approves-humira-for-moderate-to-severe-hidradenitis-suppurativa. Published 2015. Accessed April 25, 2016."},{"key":"10.1016\/j.jaad.2017.07.027_bib67","unstructured":"National Institute for Health and Care Excellence. Psoriasis: assessment and management; clinical guideline published 24 October 2012. Available at: https:\/\/www.nice.org.uk\/guidance\/cg153\/resources\/psoriasis-assessment-and-management-35109629621701. Accessed April 25, 2016."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217321564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217321564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:43:15Z","timestamp":1759272195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217321564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0190962217321564"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.07.027","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}